CCL2 and systemic lupus erythematosus: In addition, ARA290 treatment significantly decreased the serum levels of IL‐6, MCP‐1, TNF‐α and IL‐12p70, and increased the serum levels of TGF‐β and IL‐10 in MRL/lpr SLE mice, suggesting an inflammation suppressing role of ARA290 in SLE (Figure 5G).